Loading...
•
Sep 30, 2024
Shattuck Labs Q3 2024 Earnings Report
Reported financial results for the quarter ended September 30, 2024 and provided recent business highlights.
Key Takeaways
Shattuck Labs reported a net loss of $16.7 million for the quarter ended September 30, 2024, with cash and cash equivalents and investments of $90.1 million. The company is focusing on the development of SL-325 and expects its cash to fund operations into 2027.
Announced development of SL-325, a first-in-class antagonist antibody to DR3, with IND filing expected in Q3 2025.
Cash and cash equivalents and investments were approximately $90.1 million as of September 30, 2024.
R&D expenses were $16.3 million for the quarter ended September 30, 2024.
Net loss was $16.7 million for the quarter ended September 30, 2024, or $0.33 per basic and diluted share.
Shattuck Labs
Shattuck Labs
Forward Guidance
Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its Phase 1 clinical trial of SL-325.